Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nupro deleting OsteofleX supplement swelling, stiffness treatment claims at FDA's request.

This article was originally published in The Tan Sheet

Executive Summary

NUPRO DELETING OSTEOFLEX SWELLING AND STIFFNESS TREATMENT CLAIMS after receiving a Jan. 21 "courtesy letter" from FDA's Office of Special Nutritionals stating that certain claims for the dietary supplement are unapproved drug claims subject to additional regulation. "The statements that you are making for this product suggest...it is intended to treat, prevent or mitigate degenerative and/or other joint diseases and conditions and to treat muscle or mitigate muscle conditions," the letter states. Companies are required to file their structure/function claims with FDA within 30 days of marketing a dietary supplement product under the Dietary Supplement Health & Education Act.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088216

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel